Cellectis SA (CLLS) Notizie

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ:...

Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:...

Form EFFECT - Notice of Effectiveness

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS...

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:...

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ:...

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:...

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]